Claudia Chaves, MD
Neurology · Newton, MANPI 1740241736
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,129 of the $1,444 with a category attached, or 78.2%. Genentech, Inc. accounts for 97.8% of it on its own, with 2 other manufacturers making up the rest.
Across 5 payments — averaging $288.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1K
- Melinta Therapeutics, LLC$19
- AbbVie$12
Across 10 payments — averaging $7340.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$50K
- Genentech, Inc.$23K
What the payments were for
- Travel & lodging$1,12978%
- Food & beverage$31422%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 3 | $1,412 |
| Melinta Therapeutics, LLC | 1 | $19 |
| AbbVie | 1 | $12 |
How this compares
$1,444 in reported general payments places this provider in the 60th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriflunomide | 12 | $72,247 |
| Aimovig AutoinjectorErenumab-Aooe | 60 | $50,484 |
| Nurtec OdtRimegepant Sulfate | 13 | $23,616 |
| Rivastigmine | 55 | $12,325 |
| Emgality PenGalcanezumab-Gnlm | 12 | $9,339 |
| Dimethyl Fumarate | 24 | $8,828 |
| Carbidopa | 13 | $6,447 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 155 | $3,995 |
| Memantine Hcl | 75 | $3,552 |
| Gabapentin | 183 | $1,949 |
| Propranolol Hcl ErPropranolol Hcl | 38 | $1,907 |
| Donepezil Hcl | 185 | $1,759 |
| ClopidogrelClopidogrel Bisulfate | 77 | $1,194 |
| Pregabalin | 32 | $818 |
| Memantine Hcl ErMemantine Hcl | 26 | $786 |
Paid to pharmacies, not to this prescriber.
Other neurology in Newton
- Christopher WrightBoston$2.5M
- Shivang JoshiWestborough$1.2M
- Egilius SpieringsWellesley Hills$680K
- Thomas ScammellBoston$617K
- Salvatore NapoliFoxboro$613K
- Alfred SandrockBoston$490K
- Joshua KatzWellesley$462K
- Guy BuckleBrookline$450K
- Pushpa NarayanaswamiBoston$420K
- Kenneth GorsonWellesley$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.